Chromosomal instability and bladder cancer: the UroVysionTMtest in the UroScreen study
| Autor: | Georg Johnen, Dirk Taeger, Nadine Bonberg, Thomas Brüning, Christian Schwentner, Gabriele Leng, Thomas Behrens, Katarzyna Gawrych, Arnulf Stenzl, Michael Nasterlack, Karl-Dietrich Sievert, Beate Pesch, Severine Banek, Matthias Kluckert, Harald Wellhäußer |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Pathology
medicine.medical_specialty Bladder cancer medicine.diagnostic_test business.industry Urology Cell UroVysion Early detection Locus (genetics) medicine.disease chemistry.chemical_compound medicine.anatomical_structure chemistry Chromosome instability Cancer research medicine business DNA Urine cytology |
| Zdroj: | BJU International. 112:E372-E382 |
| ISSN: | 1464-4096 |
| DOI: | 10.1111/j.1464-410x.2012.11666.x |
| Popis: | What’s known on the subject? and What does the study add? UroVysion™ is a multicolour fluorescence in situ hybridisation assay that detects DNA gain at chromosomes 3, 7 and 17 and loss at the 9p21 locus in exfoliated urothelial cells. This cell-based test is time-consuming and costly compared with voided urine cytology or other molecular markers for the early detection of bladder cancer. We determined copy number changes at chromosomes 3, 7 and 17 and at the 9p21 locus with UroVysion in a prospective screening study among chemical workers. Strong correlations between DNA gains yield a similar performance in detecting bladder cancer with just one of the probes for chromosomes 3, 7 or 17 instead of all, supporting the development of a simpler and cheaper assay. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|